Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EKSO vs MYO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MYO Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 3–4 Matrix Metrics)

MYO Overall Winner 6-Pillar Tally: EKSO 0 – 5 MYO (1 Tie) Matrix Metrics: EKSO 4 – 3 MYO

As of Nov 20, 2026, Myomo Inc. (MYO) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin).

  • Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. MYO 40.1/100 SELL), MYO captures the overall institutional head-to-head verdict (3–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-21.8% vs. -119.7% operating margin) and revenue trajectory (+22.2% vs. -38.3% YoY).
  • Technical & Structure Timing Caution: EKSO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.4); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EKSO vs MYO
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65
MYO NYSE American Head-to-Head Winner
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32

6-Pillar Scorecard Institutional Category Breakdown (EKSO 0 – 5 MYO)

Columns: Metric · EKSO · MYO
1. Valuation Multiples MYO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.3x 0.9x
2. Growth & Scale MYO
Revenue Growth (YoY) -38.3% +22.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M $46M
Market Cap $42.0M $33.7M
3. Profitability & Quality MYO
Gross Margin 53.5% 70.1%
Operating Margin -119.7% -21.8%
Net Profit Margin -91.4% -33.1%
Return on Equity (ROE) -107.6% -173.5%
4. Balance Sheet & Cash Flow MYO
Cash Generation (TTM) -$11M EBITDA -$9.1M
Cash Flow Margin -86.0% EBITDA Mgn -20.0%
Net Cash / Leverage $2.54 Book/Sh · -107.6% ROE $8.9M Net Debt (3.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 266.0% (81st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EKSO (4) vs MYO (3)
Institutional Metric EKSO MYO Criterion Row Edge
Market Capitalization
Scale
$42.0M $33.7M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-38.3% +22.2% Higher Growth MYO
Operating Margin (TTM)
Profitability
-119.7% -21.8% Higher Margin MYO
Net Profit Margin
Profitability
-91.4% -33.1% Higher Margin MYO
Return on Equity (ROE)
Capital Efficiency
-107.6% -173.5% Higher ROE EKSO
52-Week Range Position
Momentum
87% ($0–$14) 16% ($1–$2) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
2.16β · 76% Vol 2.22β · 107% Vol Lower Realized Risk EKSO
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 40.1 / 100 (SELL) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$13M $46M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.5% 70.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) -$9.1M ($8.9M Net Debt (3.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYO +3.25 pp
EKSO: +25.53% · MYO: +28.78%
3M Horizon EKSO +27.43 pp
EKSO: +25.93% · MYO: -1.5%
6M Horizon EKSO +173.33 pp
EKSO: +192.8% · MYO: +19.47%
1Y Horizon EKSO +173.33 pp
EKSO: +192.8% · MYO: +19.47%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs MYO. Trailing 12-month operating profitability (EKSO -119.7% vs MYO -21.8%) and valuation multiples (EKSO N/M vs MYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M
MYO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$46M
Gross Margin70.1%
Op. Margin-21.8%
ROE / Fwd P/E-173.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EKSO vs MYO Key Questions & Quantitative Answers

As of Nov 20, 2026, Myomo Inc. (MYO) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin). Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. MYO 40.1/100 SELL), MYO captures the overall institutional head-to-head verdict (3–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-21.8% vs. -119.7% operating margin) and revenue trajectory (+22.2% vs. -38.3% YoY). Technical & Structure Timing Caution: EKSO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.4); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MYO leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with MYO at +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus $46M for MYO. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MYO.

MYO screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus MYO (-173.5% ROE) capital efficiency.

In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.